Immutep (IMMP) Non-Current Deferred Tax Liability (2014 - 2022)

Immutep (IMMP) posted Non-Current Deferred Tax Liability of $748086.4 for Q2 2022, down 48.55% on a QoQ basis from $1.5 million in Q2 2019.

Immutep (IMMP) Non-Current Deferred Tax Liability (2014 - 2022) Analysis & Trends

Immutep's Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $748086.4 for Q2 2022.

Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $748086.4 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $748086.4 (changed N/A YoY) and the FY2022 annual result came in at $748086.4, changed N/A from the prior year.
Non-Current Deferred Tax Liability was $748086.4 for Q2 2022 at Immutep, down from $1.5 million in the prior quarter.
Across five years, Non-Current Deferred Tax Liability topped out at $2.1 million in Q2 2018 and bottomed at $748086.4 in Q2 2022.
A 3-year average of $1.4 million and a median of $1.5 million in 2019 frame the typical range for Non-Current Deferred Tax Liability.
Annual changes were most pronounced in 2018 — Non-Current Deferred Tax Liability slipped 2.91% — and 2019, when it fell 29.71%.
Immutep's Non-Current Deferred Tax Liability stood at $2.1 million in 2018, then declined by 29.71% to $1.5 million in 2019, then tumbled by 48.55% to $748086.4 in 2022.
Business Quant data shows IMMP's Non-Current Deferred Tax Liability at $748086.4 in Q2 2022, $1.5 million in Q2 2019, and $2.1 million in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Immutep	567.77 Mn	567.77 Mn	-

Download Data